Introduction {#Sec1}
============

Type 2 diabetes is emerging as a major health issue, with the global prevalence estimated to reach 300 million people by the year 2025 \[[@CR1]\]. This increase has been linked to an ageing population, lifestyle changes and an increase in global obesity. At present, the oral anti-hyperglycaemic drug metformin is a first-line treatment for type 2 diabetes, and predominantly acts through decreasing glucose production by the liver \[[@CR2]\]. In addition to reducing hyperglycaemia, metformin treatment in diabetic patients has been linked to decreased rates of macrovascular disease and mortality \[[@CR3]\]. Despite receiving treatment, however, many diabetic patients are still at increased risk of developing complications associated with the disease \[[@CR4], [@CR5]\].

Diabetic retinopathy is a major complication of types 1 and 2 diabetes \[[@CR6]\]. Characterised and diagnosed by alterations in the retinal vasculature \[[@CR7]\], studies have shown that changes to neurons and glia occur during diabetic retinopathy \[[@CR8]--[@CR10]\], with functional tests in humans and animal models indicating that neuronal dysfunction is present prior to overt vascular damage \[[@CR11]--[@CR13]\]. The underlying mechanism of neuronal dysfunction is unknown, but connections have been made to abnormal Na/K-ATPase activity \[[@CR14]\], shortened photoreceptor segments \[[@CR15]\] and differences in the light and dark vs colour visual pathways \[[@CR16]\]. More than 90% of type 1 and 60% of type 2 diabetes patients develop some form of retinopathy following two decades of diabetes \[[@CR6]\], despite receiving treatment for hyperglycaemia. This implies that hyperglycaemia-associated pathological retinal changes are not fully ameliorated by treatment. As such, it is necessary to understand the changes in the retina induced by diabetes, which pathways are affected by disease and the degree to which treatment ameliorates these alterations.

This study examined the retinal membrane proteome of the *db/db* mouse model of type 2 diabetes, and compared it with the proteome of non-diabetic mice and diabetic mice treated with metformin (*dbM*). Diabetic *db/db* mice have a mutation in the *Lepr* gene (encoding the leptin receptor), resulting in excessive food consumption and the development of obesity, hyperglycaemia and insulin resistance \[[@CR17]\]. Pathological changes in the retinas of *db/db* mice include breakdown of the blood--retina barrier, acellular capillaries and neuronal dysfunction \[[@CR18]--[@CR20]\]. The membrane proteome is of particular interest in understanding changes in the diabetic retina, as it consists of transporters, receptors and signalling proteins that might be altered in disease or function as targets of drug treatment.

Methods {#Sec2}
=======

Experimental animals {#d30e561}
--------------------

Mice (*db/db* \[BKS.Cg-m+/+*Lepr*^*db/db*^\] and wild-type \[BKS.Cg-m+/+*Lepr*^m/m^\]; Jackson Laboratories, Bar Harbor, ME, USA) were bred and housed in single ventilated cages (SealsafePlus AERO IVC Greenline, Tecniplast, Hohenpeissenberg, Germany) at 22 ± 1°C, with a 12:12 h light:dark cycle and controlled humidity, in the German Mouse Clinic, Helmholz Center Munich \[[@CR21], [@CR22]\]. All procedures were performed with approval from the Government of Upper Bavaria (reference no. 55.2-1-54-2531-70-07) and adhered to the Principles of Laboratory Animal Care (NIH publication no. 85-23, revised 1985, <http://grants1.nih.gov/grants/olaw/references/phspol.htm>).

Male wild-type and *db/db* mice were fed a high-fat diet postweaning (S0372-E010, ssniff Spezialdiäten, Soest, Germany). At 8 weeks, mice were fasted for 4 h and weighed, and blood glucose (Contour, Bayer Vital, Leverkusen, Germany) and HbA~1c~ (A1cNow^+^, Bayer Vital) concentrations were measured. Inclusion criteria for diabetic mice were weight greater than 44 g and blood glucose above 19.43 mmol/l. Mice that met these criteria were matched into two cohorts: one cohort was treated with metformin (*dbM*, 300 mg kg^−1^ day^−1^; Sigma Aldrich, Munich, Germany), while the other cohort and wild-type mice were given placebo (*n* = 10 in each group). Metformin was dissolved in 0.5% placebo solution (95% hydroxyethylcellulose 250G Pharm, Fagron, Barsbüttel, Germany; 5% Solutol HS15, BASF, Ludwigshafen, Germany) and applied daily by gavage. At 10 weeks, mice were fasted for 4 h, weighed, had blood glucose and HbA~1c~ measurements taken and were killed with an isoflurane overdose 18 h after treatment. The eyes were enucleated, and retinas were either dissected, frozen in liquid nitrogen and stored at −80°C until further processing, or the anterior chamber was removed and the posterior eyecup fixed in 4% paraformaldehyde in 0.1 mol/l phosphate buffer (PB; pH 7.4), and processed for immunofluorescence \[[@CR23]\]. Figure [1](#Fig1){ref-type="fig"} shows body weight, blood glucose and HbA~1c~ levels.Fig. 1(**a**) Body weight, (**b**) blood glucose and (**c**) HbA~1c~ measurements for wild-type, *db/db* and *dbM* mice. *db/db* and *dbM* mice had significantly increased body weight compared with wild-type mice (wild-type 21.88 ± 0.371 g; *db/db* 52.36 ± 1.207 g; *dbM* 51.44 ± 1.013 g; *p* \< 0.0001). Blood glucose was significantly increased in *db/db* and *dbM* mice (wild-type 5.899 ± 0.296 mmol/l; *db/db* 27.76 ± 0.625 mmol/l; *dbM* 22.05 ± 2.009 mmol/l; *p* \< 0.0001), as were HbA~1c~ values (wild-type 20.06 ± 0.400 mmol/mol; *db/db* 56.57 ± 2.543 mmol/mol; *dbM* 45.00 ± 2.400 mmol/mol; *p* \< 0.0001). Diabetic *db/db* and *dbM* mice had similar body weight (*p* \> 0.999), but *dbM* mice had significantly decreased blood glucose (*p* \< 0.001) and HbA~1c~ values (*p* \< 0.001). \*\**p* \< 0.001, \*\*\*\**p* \< 0.0001. To convert values for HbA~1c~ in mmol/mol into %, multiply by 0.09148 and add 2.152, or use the conversion calculator at [www.hba1c.nu/eng/](http://www.hba1c.nu/eng/)

Proteomic sample preparation {#d30e738}
----------------------------

Membrane proteins were extracted as previously described \[[@CR24]\]. Frozen retinal samples (*n* = 9 per group, in pools of three) were mechanically homogenised in a high-salt buffer (2 mol/l NaCl; 10 mmol/l HEPES NaOH, pH 7.4; 1 mmol/l EDTA), lightly centrifuged (61 *g*, 5 min, 4°C) to remove non-grinded tissue and then strongly centrifuged (17,500 *g*, 30 min, 4°C). The remaining pellet was repeatedly homogenised in a high pH buffer (0.1 mol/l Na~2~CO~3~, pH 11.3; 1 mmol/l EDTA), incubated on ice and centrifuged (17,500 *g*, 30 min, 4°C), with the supernatant fraction removed following each round. Following homogenisation, membrane protein pellets were solubilised in 36 μl of 50 mmol/l ammonium bicarbonate and 4 μl 2% RapiGest (Waters, Milford, MA, USA), reduced with 2 μl of 100 mmol/l dithiothreitol and incubated at 60°C for 10 min. Samples were alkylated with 2 μl of 300 mmol/l iodoacetamide at room temperature in the dark and digested with 4 μl trypsin (0.5 mg/ml, Promega, Madison, WI, USA) at 37°C overnight. The reaction was stopped with concentrated HCl. This was followed by centrifugation, with the soluble phase collected for liquid chromatography tandem mass spectrometry (LC-MS/MS) analysis.

Mass spectrometry {#d30e765}
-----------------

LC-MS/MS analysis was performed on an UltiMate 3000 nano rapid separation LC system (Dionex, Idstein, Germany) coupled to a linear trap quadrupole Velos mass spectrometer (Thermo Fisher Scientific, Schwerte, Germany) \[[@CR25]\]. Samples were automatically loaded into a HPLC system (Dionex) at a 6 μl/min flow rate, in 0.5% trifluoracetic acid in HPLC-grade water onto an Acclaim PepMap100 column (75 μm inner diameter ×2 cm, C18, 3 μm, 100 Å, Dionex). After 5 min, peptides were eluted and separated on an Acclaim PepMap RSLC column (75 μm × 25 cm, C18, 2 μm, 100 Å, Dionex) by a linear gradient from 2% to 35% of buffer B (80% acetonitrile, 0.08% formic acid in HPLC-grade water) in buffer A (2% acetonitrile, 0.1% formic acid in HPLC-grade water) at a 300 nl/min flow rate over 150 min. Remaining peptides were eluted by a short gradient from 35% to 100% buffer B in 5 min. The eluted peptides were analysed online in the linear trap quadrupole Velos. From the high-resolution MS prescan with a mass range from 300 to 1,500 Da, the ten most intense peptide ions were automatically selected for fragment analysis in the linear ion trap if they exceeded an intensity of 200 counts and if they were at least doubly charged. Target peptides selected for MS/MS were dynamically excluded for 20 s.

Label-free analysis {#d30e773}
-------------------

Acquired spectra (Thermo raw files) were analysed using Progenesis LC-MS software (Version 4.0, Nonlinear Dynamics, Newcastle upon Tyne, UK) \[[@CR24]\]. The profile data of the MS scans were transformed into peak lists with respective intensities, abundances and *m/z* values. MS/MS spectra were treated similarly. Using one sample as the reference, the retention times of the other samples were manually and automatically aligned to a maximal overlay of the two-dimensional features. Features with one charge or more than eight charges were excluded from further analyses. Samples were then allocated to their respective experimental groups (wild-type, *db/db* or *dbM*).

All MS/MS spectra were exported in Mascot generic format (mgf) and used for peptide identification with Mascot (version 2.4; Matrix Science, Boston, MA, USA) using the Ensembl mouse protein database ([www.ensembl.org](http://www.ensembl.org/); *Mus musculus*; release 66 NCBIM37, 56,416 sequences, <ftp://ftp.ensembl.org/pub/current_fasta/mus_musculus/>). Search variables were: 10 ppm peptide mass tolerance; 0.6 Da MS/MS tolerance; one missed cleavage allowed; methionine oxidation, asparagine and glutamine deamidation as variable modifications; and carbamidomethylation as a fixed modification. The Mascot-integrated decoy database search calculated a false discovery rate of less than 1% when searching was performed on the concatenated mgf files with a percolator ion score cut-off of 15, and the significance threshold *p* adjusted to reach the maximum false discovery rate. Identifications were re-imported into Progenesis. All unique peptides were included for quantification. Total cumulative protein abundance was calculated by summing the intensities of the individual peptides allocated to the respective protein; when two peptides are identified as belonging to protein X, if the intensity of peptide A is 1,000 and peptide B is 2,000, the total abundance of protein X is 3,000 \[[@CR24]\]. No minimal thresholds were set for the method of peak picking or selection of data to use for quantifications. This study used proteins identified and quantified by at least two peptides for further analysis.

Protein network and pathway enrichment analysis {#d30e811}
-----------------------------------------------

Protein interaction maps were created by uploading gene identifiers and fold changes (*db*/wild-type) for significantly different proteins into the Genomatix Pathway System (GePS, version 2.3.0, [www.genomatix.de](http://www.genomatix.de/), accessed 27 March 2013, Genomatix, Munich, Germany). Interaction maps were based on *Mus musculus* and 'function word' as co-citation level for literature mining. The network was extended by ten genes via frequent co-citations for *Ctbp2* (protein name RIBEYE), *Slc17a7* (vesicular glutamate transporter 1 \[VGLUT1\]), *Ndufa4* (NDUA4). *Ndufa9* (NDUA9), *Ndufa11* (NDUAB), *Ndufa12* (NDUAC), *Ndufa13* (NDUAD), *Ndufb6* (NDUB6) and *Ndufb10* (NDUBA), and connected by the shortest path. Candidates without interactions were removed. Based on *db*/wild-type fold-change, upregulated proteins were coloured green and downregulated proteins were coloured red. Grey colouring represented network-extended proteins.

Pathway enrichment analyses were performed for down- or upregulated proteins using Ingenuity Pathway Analysis (IPA; [www.ingenuity.com](http://www.ingenuity.com/), accessed 13 December 2012, Ingenuity Systems, CA, USA). Protein lists were uploaded with Ensembl mouse accession numbers and core analysis was performed to identify the biological functions most significantly represented in the dataset. The analysis used the Ingenuity Knowledge Base (Ingenuity Systems) as the reference set, and considered molecules and/or relationships with *Mus musculus* as the species in experimentally observed results. *p* values were calculated using Fisher's exact test to determine the probability that a function or disease assigned to the dataset would occur by chance.

Metformin quantification {#d30e872}
------------------------

Retinal metformin levels were determined using HPLC-MS/MS quantification (unpublished data, S Zukunft, C Muschet, J Adamski). Frozen retinal samples of placebo- and metformin-treated *db/db* mice were transferred into dry-ice-cooled 1.4 mm Precellys tubes (Peqlab Biotechnologie, Erlangen, Germany) and homogenised in HPLC-grade methanol (20 μl/mg tissue; AppliChem, Darmstadt, Germany). The homogenates were diluted 1:100 in HPLC-grade methanol containing 5 ng/ml deuterium-labelled metformin (metformin-d6), which served as an internal standard. MS/MS measurements were performed on a QTRAP 5500 System (AB Sciex, Darmstadt, Germany) coupled to an 1260 Infinity Series HPLC (Agilent, Böblingen, Germany) and an HTC-xt PAL autosampler (CTC Analytics, Zwingen, Switzerland), controlled by Analyst 1.6.1 software (AB Sciex). Reverse-phase LC was performed applying a methanolic isocratic mobile phase. Metformin was identified by multiple reaction monitoring using 130.04/60.00 Da as Q1/Q3 mass pairs for metformin and 136.09/60.00 Da for metformin-d6. Quantification was assessed by comparing sample peak areas with those of a methanol-dissolved metformin standard curve.

Relative qRT-PCR quantification {#d30e880}
-------------------------------

Total RNA was isolated from wild-type and *db/db* retinas (*n* = 3 per group) \[[@CR26]\]. Samples were homogenised in 750 μl TRIzol (Invitrogen, Karlsruhe, Germany) and incubated for 5 min. Chloroform (150 μl) was added, followed by incubation for 3 min and centrifuged (17,500 *g*, 15 min, 4°C). The supernatant fraction was transferred to a new tube with 375 μl isopropanol, incubated for 10 min and centrifuged (17,500 *g*, 10 min, 4°C). The pellet was washed with 75% ethanol and treated with the RQ1 RNase-Free DNase kit (Promega) to eliminate contaminating genomic DNA. Total RNA was quantified using a NanoDrop photometer (Thermo Fisher Scientific) and cDNA generated using the Fermentas RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific) following the manufacturer's instructions. To improve the yield, oligo(dT)~20~-primers and random hexamer primers were used for synthesis. *Slc17a7* gene expression was assessed relative to the *Hprt1* housekeeping gene (primer sequences in Electronic Supplementary Material \[ESM\] Table [1](#MOESM1){ref-type="media"}). Real-time PCR was performed using a LightCycler 480 (Roche Diagnostics, Mannheim, Germany) using the KAPA SYBR FAST qPCR MasterMix for Roche LightCycler 480 Kit (Peqlab Biotechnologie).

Immunofluorescence and photography {#d30e913}
----------------------------------

VGLUT1 expression was examined with immunofluorescence (*n* = 6) \[[@CR23]\]. Vertical cryosections of 12 μm were blocked with 10% normal goat serum, 1% BSA and 0.5% Triton-X 100 in PB for 1 h, and incubated in anti-VGLUT1 antibody (AB\#5905, Millipore, Schwabach, Germany) diluted 1:5,000 in buffer (3% normal goat serum, 1% BSA and 0.5% Triton-X 100 in PB) overnight at room temperature. After rinsing, sections were incubated with goat anti-guinea pig Alexa Fluor 488 secondary antibody (Invitrogen) diluted 1:1,000 in buffer for 90 min, washed in PB and coverslipped. All sections were photographed with constant variables on an AxioImager Z1 with ApoTome attachment (Zeiss, Göttingen, Germany). Mean intensities of VGLUT1 labelling in the outer plexiform layer (OPL) and inner plexiform layer (IPL) were measured using the Definiens Enterprise Image Intelligence Suite (Definiens, Munich, Germany).

Statistical analysis {#d30e924}
--------------------

All values are expressed as mean ± SEM. Body weight, blood glucose and HbA~1c~ were analysed with one-way ANOVA and Bonferroni post hoc test using an alpha of 0.05. All other data were analysed using Student's *t* test. Results were considered significant at *p* \< 0.05.

Results {#Sec3}
=======

Identification of proteins and protein networks in diabetic retina {#d30e941}
------------------------------------------------------------------

A total of 844 proteins were identified in the membrane-enriched fractions of retinal tissue from wild-type, *db/db* and *dbM* mice, of which 513 proteins were identified and quantified by more than one peptide and used for further analysis (ESM Tables [2](#MOESM2){ref-type="media"} and [3](#MOESM3){ref-type="media"}). Analysis of the subcellular location of the identified proteins was completed using the UniProtKB/Swiss-Prot database. Overall, 64% of identified proteins were annotated with 'membrane' or variations thereof (ESM Fig. [1](#MOESM9){ref-type="media"}), which is comparable with other membrane proteome studies \[[@CR24]\].

A total of 98 proteins were differentially abundant (*p* \< 0.05) between wild-type and *db/db* retinas, of which 80 were downregulated and 18 upregulated (ESM Table [4](#MOESM4){ref-type="media"}). A protein interaction network map was generated using GePS to identify functional clusters affected by diabetes (Fig. [2](#Fig2){ref-type="fig"}). Nine candidates were chosen to extend the network: *Ndufa4*, *Ndufa9*, *Ndufa11*, *Ndufa12*, *Ndufa13*, *Ndufb6* and *Ndufb10*, which are subunits of NADH dehydrogenase (ubiquinone) I, also known as complex I, from the electron transport chain; and *Ctbp2* (RIBEYE) and *Slc17a7* (VGLUT1), which are known to have important roles in retinal synaptic transmission. Extending by the most frequently co-cited genes and then removing results without connections produced a loosely interconnected network of 41 proteins from the dataset, with 12 additional proteins. Two proteins added to the network formed many connections with other proteins from the dataset and with other added proteins: *Ins2*, the mouse orthologue of insulin (*INS*), and *Trp53*, the mouse orthologue of tumour protein 53 (*TP53*).Fig. 2Interaction map of differentially abundant retinal proteins in diabetes. A total network was generated with GePS using functional word as connector. Proteins abbreviations are based on official gene symbols (NCBI Entrez Gene). Upregulated proteins are presented in green, downregulated proteins in red and network-extended proteins in grey. The network indicates a moderate degree of functional interaction among proteins affected by diabetes

Pathway enrichment analysis with IPA was completed to determine the biological processes most affected in diabetic retinas. The 80 proteins with decreased abundances in diabetes were significantly associated with 367 biological functions (ESM Table [5](#MOESM5){ref-type="media"}). Table [1](#Tab1){ref-type="table"} lists the top five molecular and cellular functions. Cell-to-cell signalling was the highest ranking category with 11 annotated functions, of which synaptic transmission was the most significantly annotated (*p* = 7.93 × 10^−6^). The synaptic transmission annotation contained eight proteins, which included several proteins identified in the GePS protein interaction network. Other highly ranking categories include molecular transport and amino acid metabolism. IPA identified 210 significantly enriched biological functions associated with the 18 upregulated proteins (ESM Table [6](#MOESM6){ref-type="media"}). Cell death and survival was the highest ranking molecular function, with four proteins and four functions (Table [2](#Tab2){ref-type="table"}), of which recovery of retinal rods was the most significantly annotated function (*p* = 1.17 × 10^−6^). These biological functions were not enriched when the entire set of 513 detected and quantified proteins underwent pathway analysis (ESM Table [7](#MOESM7){ref-type="media"}).Table 1Top five molecular and cellular functions associated with proteins downregulated in diabetic retinasCategory and annotations*p* valueMoleculesNo. moleculesCell-to-cell signalling and interaction Synaptic transmission7.93 × 10^−6^DPP6, GLRB, SLC12A5, SLC17A7, SLC1A3, SV2A, SV2B, VDAC18 Long-term potentiation4.10 × 10^−3^DPP6, KRAS, SLC17A7, SYNGR1, VDAC15 Long-term potentiation of synapse4.59 × 10^−3^DPP6, SLC17A7, SYNGR1, VDAC14 Accumulation of 5-hydroxytryptamine4.81 × 10^−3^MAOA1 Sequestration of neurotransmitter4.81 × 10^−3^SLC17A71 Release of [l-]{.smallcaps}glutamic acid6.87 × 10^−3^SLC17A7, SLC1A32 Paired-pulse facilitation of synapse1.81 × 10^−2^SYNGR1, VDAC12 Aggregation of neurons2.38 × 10^−2^ATP1B11 Catabolism of dopamine2.38 × 10^−2^MAOA1 Plasticity of synapse4.23 × 10^−2^KRAS, SYNGR12 Formation of adherens junctions4.25 × 10^−2^KRAS1Cellular assembly and organisation Activation of permeability transition pores2.28 × 10^−5^SLC25A4, SLC25A52 Fragmentation of microtubules4.81 × 10^−3^TUBB1 Organisation of axon terminals4.81 × 10^−3^MAOA1 Expansion of thalamocortical axons9.59 × 10^−3^MAOA1 Quantity of thalamocortical axons9.59 × 10^−3^MAOA1 Segregation of sensory projections9.59 × 10^−3^MAOA1 Morphology of Golgi apparatus1.44 × 10^−2^TMED101 Organisation of Golgi apparatus2.85 × 10^−2^TMED101 Formation of adherens junctions4.25 × 10^−2^KRAS1 Morphology of mitochondria4.35 × 10^−2^NDUFA13, SLC25A42Amino acid metabolism Import of [l-]{.smallcaps}glutamic acid6.81 × 10^−5^SLC17A7, SLC1A32 Synthesis of GABA4.81 × 10^−3^SLC1A31 Synthesis of [l-]{.smallcaps}glutamic acid4.81 × 10^−3^SLC1A31 Release of [l-]{.smallcaps}glutamic acid6.87 × 10^−3^SLC17A7, SLC1A32 Metabolism of [l-]{.smallcaps}glutamic acid1.91 × 10^−2^SLC1A31Molecular transport Import of [l-]{.smallcaps}glutamic acid6.81 × 10^−5^SLC17A7, SLC1A32 Transport of anions1.39 × 10^−4^GLRB, SLC12A5, SLC4A3, VDAC14 Transport of ions5.13 × 10^−4^ATP2B1, CAMK2D, CAMK2G, GLRB, SLC12A5, SLC4A3, VDAC17 Transport of molecules1.51 × 10^−3^ATP2B1, CAMK2D, CAMK2G, GLRB, SLC12A5, SLC17A7, SLC1A3, SLC4A3, TMED10, VDAC110 Transport of Ca^2+^3.14 × 10^−3^ATP2B1, CAMK2D, CAMK2G3 Accumulation of 5-hydroxytryptamine4.81 × 10^−3^MAOA1 Exchange of ADP4.81 × 10^−3^SLC25A41 Exchange of ATP4.81 × 10^−3^SLC25A41 Release of lactic acid4.81 × 10^−3^SLC1A31 Translocation of ADP4.81 × 10^−3^VDAC11 Release of [l-]{.smallcaps}glutamic acid6.87 × 10^−3^SLC17A7, SLC1A32 Transport of chloride6.87 × 10^−3^GLRB, SLC12A52 Redistribution of cholesterol1.91 × 10^−2^ATP1A11 Transport of cations2.47 × 10^−2^ATP2B1, CAMK2D, CAMK2G, SLC12A54Small-molecule biochemistry Import of [l-]{.smallcaps}glutamic acid6.81 × 10^−5^SLC17A7, SLC1A32 Accumulation of 5-hydroxytryptamine4.81 × 10^−3^MAOA1 Exchange of ADP4.81 × 10^−3^SLC25A41 Exchange of ATP4.81 × 10^−3^SLC25A41 Oxidation of lactic acid4.81 × 10^−3^MLXIPL1 Release of lactic acid4.81 × 10^−3^SLC1A31 Sequestration of neurotransmitters4.81 × 10^−3^SLC17A71 Synthesis of GABA4.81 × 10^−3^SLC1A31 Synthesis of [l-]{.smallcaps}glutamic acid4.81 × 10^−3^SLC1A31 Translocation of ADP4.81 × 10^−3^VDAC11 Release of [l-]{.smallcaps}glutamic acid6.87 × 10^−3^SLC17A7, SLC1A32 Metabolism of [l-]{.smallcaps}glutamic acid1.91 × 10^−2^SLC1A31 Redistribution of cholesterol1.91 × 10^−2^ATP1A11 Catabolism of dopamine2.38 × 10^−2^MAOA1 Synthesis of glucocorticoids2.85 × 10^−2^ATP1A11Protein abbreviations are based on official gene symbols (NCBI Entrez Gene)Table 2Top five molecular and cellular functions associated with proteins upregulated in diabetic retinaCategory and annotations*p* valueMoleculesNo. moleculesCell death and survival Recovery of retinal rods1.17 × 10^−6^ABCA4, RGS9BP2 Delay in recovery of retinal rods1.11 × 10^−3^ABCA41 Apoptosis of endothelial cell lines4.45 × 10^−3^CDH21 Apoptosis of photoreceptors1.22 × 10^−3^ROM11Cellular compromise Degeneration of photoreceptors1.07 × 10^−3^ABCA4, ROM12 Neurodegeneration of photoreceptors6.67 × 10^−3^ROM11 Degeneration of retinal rods1.33 × 10^−2^ROM11Amino acid metabolism Transport of [l-]{.smallcaps}histidine1.11 × 10^−3^SLC38A31 Transport of [l-]{.smallcaps}glutamine2.23 × 10^−3^SLC38A31Carbohydrate metabolism Quantity of *N*-retinylidene-phosphatidylethanolamine1.11 × 10^−3^ABCA41Cell morphology Size of rod outer segment disks1.11 × 10^−3^ROM11 Abnormal morphology of photoreceptor outer segments1.12 × 10^−3^ABCA4, ROM12 Blebbing of nucleus2.23 × 10^−3^LMNB11 Length of rod outer segments4.45 × 10^−3^ROM11 Abnormal morphology of rod outer segments1.55 × 10^−2^ROM11 Innervation of muscle2.43 × 10^−2^LMNB11 Abnormal morphology of photoreceptors3.73 × 10^−2^ABCA41 Extension of axons4.16 × 10^−2^CDH21Protein abbreviations are based on official gene symbols (NCBI Entrez Gene)

Effect of metformin on diabetic retinas {#d30e2389}
---------------------------------------

In order to confirm that metformin crossed the blood--retinal barrier, a direct measurement of metformin levels was conducted on retinal tissue from 4 h drug-treated *db/db* mice. A total of 8.52 ± 1.28 nmol/g of metformin was detected in retinas from drug-treated mice, while none was detected in the placebo-treated group.

Retinal membrane proteins from metformin-treated *db/db* mice were analysed to examine whether drug treatment ameliorated diabetes-induced changes. A total of 63 proteins were differentially abundant between the *db/db* and *dbM* samples (*p \<* 0.05, ESM Table [8](#MOESM8){ref-type="media"}). Combining these results with the analysis of wild-type vs *db/db* samples, 43 of the identified proteins occurred in both datasets (Fig. [3](#Fig3){ref-type="fig"}); 55 were not significantly altered, and a further 20 proteins were not detected in the wild-type vs *db/db* dataset. Six of the 43 normalised proteins were complex I subunits: NDUA4, NDUA9, NDUAC, NDUAD, NDUB6 and NDUBA. The abundance of these proteins was similar in wild-type and *dbM* mice, indicating normalisation through metformin treatment (Fig. [4](#Fig4){ref-type="fig"}). Of the 55 proteins from the wild-type vs *db/db* dataset that did not exhibit a significant change following metformin treatment, some protein abundances e.g. VGLUT1, synaptogyrin 1 (SNG1) and sodium-coupled neutral amino acid transporter 3 (S38A3) were different from wild-type levels following treatment (Fig. [5a--c](#Fig5){ref-type="fig"}), while others e.g. opsin 1 blue -sensitive (OPSB), NDUAB and plasma membrane calcium ATPase (ATP2B3) showed large variations in sample protein levels (Fig. [5d--f](#Fig5){ref-type="fig"}). However, protein abundances demonstrated a trend towards normalisation. Some of the 20 proteins significantly altered in *db/db* vs *dbM* mice, but not in wild-type vs *db/db* mice, could have resulted from variations in sample abundance (Fig. [6a, b](#Fig6){ref-type="fig"}). Nevertheless, abundances of other proteins e.g. opsin 2 rhodopsin (OPSD), retinol dehydrogenase 12 (RDH12), cyclic nucleotide gated channel alpha 1 (CNGA1) and 5′-nucleotidase (5NTD) were dramatically altered following metformin treatment (Fig. [6c--f](#Fig6){ref-type="fig"}).Fig. 3Venn diagram showing the number of proteins identified in retinas from wild-type vs *db/db* (dark grey) and *db/db* vs *dbM* (light grey) mice. A total of 98 proteins were identified as being differentially abundant in diabetic vs non-diabetic mice. Metformin treatment produced 63 differentially abundant proteins from untreated diabetic mice. A total of 43 proteins were identified as occurring in both datasets (overlap; white)Fig. 4Complex I proteins normalised by metformin treatment as measured by MS. NDUA4 (**a**), NDUA9 (**b**), NDUAC (**c**), NDUAD (**d**) and NDUB6 (**e**) abundances were significantly decreased in *db/db* mice compared with wild-type and *dbM* mice, while NDUBA (**f**) was increased. Levels of these proteins were comparable in *dbM* and wild-type mice. \**p* \< 0.05. Protein abundances are arbitrary unitsFig. 5Selected non-significantly different proteins between *db/db* and *dbM* treatment groups, as measured by MS. While all of the proteins presented were significantly altered from wild-type levels, they were not significantly affected (*p* \> 0.05) by metformin treatment. (**a**) VGLUT1, (**b**) SNG1, (**c**) S38A3, (**d**) OPSB, (**e**) NDUAB and (**f**) ATP2B3 protein abundance. \**p* \< 0.05. Protein abundances are arbitrary unitsFig. 6Selected significantly different proteins between *db/db* and *dbM* treatment groups. Mass spectrometric measurements showed variations in the individual wild-type sample abundances of (**a**) monocarboxylate transporter 1(MOT1) and (**b**) signal-regulatory protein alpha (SIRPA), demonstrating that some proteins may not have been identified as significantly altered between wild-type and *db/db* measurements. However, metformin treatment did change the abundances of non-altered proteins, such as (**c**) OPSD, (**d**) RDH12, (**e**) CNGA1 and (**f**) 5NTD. \**p* \< 0.05. Protein abundances are arbitrary units

Slc17a7/VGLUT1 alterations in diabetic retinas {#d30e2594}
----------------------------------------------

VGLUT1, encoded by *Slc17a7*, was selected for validation because it was differentially abundant between wild-type and *db/db* samples, not altered by metformin treatment and identified by GePS and IPA as having significant protein connections and functions. Using quantitative PCR, gene expression of *Slc17a7* in diabetic retinas was found to be 41% of wild-type expression (Fig. [7](#Fig7){ref-type="fig"}). Because VGLUT1 is expressed at the glutamatergic synapses of photoreceptors and bipolar cells in the OPL and IPL \[[@CR27]\], immunofluorescence was used to determine if VGLUT1 downregulation occurred in a specific location. Strong punctate labelling with VGLUT1 antibody was observed in the OPL and IPL in wild-type animals (Fig. [8a](#Fig8){ref-type="fig"}). In comparison, expression of VGLUT1 appeared to be decreased in both corresponding layers of the *db/db* retina (Fig. [8b](#Fig8){ref-type="fig"}). Quantification of VGLUT1 immunoreactivity found a significant decrease in *db/db* mice in the OPL (*p* \< 0.01, Fig. [8c](#Fig8){ref-type="fig"}) and an even greater reduction in the IPL, compared with wild-type (*p* \< 0.001, Fig. [8d](#Fig8){ref-type="fig"}). Taken together, these data indicate decreases in retinal VGLUT1 protein and gene expression, and anatomic localisation in diabetes.Fig. 7Changes in *Slc17a7* gene expression in a mouse model of diabetes. The mRNA level of *Slc17a7* was decreased in diabetic retinas (*db/db*) compared with non-diabetic wild-type animals. Data are expressed as mean ± SDFig. 8Altered retinal VGLUT1 immunoreactivity in diabetes. Retinas from (**a**) wild-type and (**b**) diabetic mice were assessed for VGLUT1 immunolabelling. The intensity of VGLUT1 labelling was assessed in (**c**) the OPL and (**d**) the IPL. In wild-type retinas, VGLUT1 labelling was strongly present in the OPL with punctate labelling in the IPL. The intensity of VGLUT1 labelling appeared decreased in diabetic retinas in both layers. Quantification of fluorescence intensity indicated significant decreases in both the OPL (\*\**p* \< 0.01) and the IPL (\*\*\**p* \< 0.001). Scale bar: 50 μm. GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer

Discussion {#Sec4}
==========

We used label-free quantitative MS to examine the retinal membrane proteome at an early stage of diabetes. We identified pathways most affected by disease and investigated the effect of metformin on the membrane proteome of the diabetic retina. Our study revealed 98 differentially abundant proteins between wild-type and diabetic mice. Bioinformatics analysis indicated that these proteins were associated with cell signalling, particularly synaptic transmission. A total of 63 differentially abundant retinal membrane proteins were detected in diabetic mice treated with metformin compared with untreated diabetic retinas. Of these, 43 were found to overlap with the wild-type vs diabetes dataset, leaving 55 proteins not significantly affected by metformin treatment. Finally, qPCR and immunofluorescence analyses indicated a significant decrease in VGLUT1 protein and gene expression levels in the diabetic retina.

Proteomic studies of diabetes and diabetic complications can provide valuable information on the pathogenesis of the disease by identifying and quantifying biomarkers. The earliest proteomic diabetic retinopathy studies were conducted in 2007. Comparing healthy and diabetic rat retinas, two-dimensional electrophoresis was used to separate proteins, which were subsequently identified using matrix-assisted laser desorption/ionisation time of flight (MALDI-TOF) and MS/MS. Alterations in a number of proteins, including succinyl CoA ligase, phosducin, glutamine synthetase and αA-crystallin, were described \[[@CR28], [@CR29]\]. Later studies identified upregulation of α-, β-, and γ-crystallin isoforms, but reported conflicting results as to whether insulin treatment normalised these alterations \[[@CR30], [@CR31]\]. The identification of changes to crystallin isoforms is notable as these proteins belong to the heat-shock protein family and are involved in apoptosis regulation and vascular remodelling \[[@CR32], [@CR33]\]. Despite these promising results, relatively few proteomic studies have since been conducted on the diabetic vitreous or retina \[[@CR28]--[@CR31], [@CR34]--[@CR38]\], and none has concentrated specifically on the membrane proteome.

We have focused on the membrane proteome for a number of reasons. Membrane-bound proteins include signal transducers, transporters and receptors, which are likely to be among the first proteins affected by systemic hyperglycaemia and, being on the cell surface, are possible therapeutic targets. A previous proteomic diabetic retinopathy study commented on the relatively low abundance of membrane proteins compared with cytosolic proteins in their results \[[@CR34]\], but improvements in sample preparation methods have now made it possible to analyse this specific subset of proteins \[[@CR24]\]. Finally, immunohistochemical studies examining retinas from other diabetic animal models have reported defects in cell membrane proteins such as occludin \[[@CR39]\], connexin-26 \[[@CR23]\] and connexin-43 \[[@CR40]\]. These proteins were not differentially abundant in our study; however, a number of proteins in our dataset were associated with cell signalling, particularly in synaptic transmission.

Decreased abundances of synaptic proteins may have relevance regarding the neuronal dysfunction observed in diabetic retinopathy. A number of electroretinogram studies in humans and animal models have reported decreases in inner retinal waveform components \[[@CR12], [@CR23], [@CR41]\], indicating that postreceptoral neurons are particularly susceptible in diabetic retinopathy. The cause of these defects is unknown, but the downregulation of synaptic transmission proteins may indicate alterations in the steps required to transmit synaptic signals. VGLUT1 is the major transporter responsible for loading the excitatory neurotransmitter glutamate into synaptic vesicles, and is expressed at ribbon synapses in photoreceptors in the OPL and 'ON' bipolar cells in the IPL \[[@CR27]\]. In our study, VGLUT1 was decreased in the diabetic retina at the mRNA and protein levels, and was not normalised by metformin treatment. As the electroretinogram is a serial waveform corresponding to the activity of different neuronal populations \[[@CR42]\], a decrease in VGLUT1 might result in altered rates and amounts of glutamate loading, affecting the magnitude of signal transmission from photoreceptors to bipolar cells and between postreceptoral neurons.

While metformin has been detected in the central nervous system \[[@CR43]\], this is the first study to demonstrate its presence in the retina. Metformin was detected at comparable levels with those found in different brain regions of metformin-treated rats \[[@CR43]\], indicating that retinal alterations following drug treatment could be caused by a direct effect. We observed the downregulation of complex I subunits in the *db/db* retina and subsequent normalisation by metformin. Decreases in the ratio of free cytosolic NAD^+^ to NADH in diabetic retinas have been linked to altered aldose reductase activity \[[@CR44], [@CR45]\]; however, as complex I catalyses the transfer of electrons from NADH to coenzyme Q, reduced abundance of complex I subunits could lessen the dehydrogenase ability, resulting in increased free NADH. In contrast to our results, previous work using rat livers found that metformin directly inhibited complex I \[[@CR46]\]. The difference in metformin response between these studies could be attributed to experimental design. First, the rats received metformin for 5 days, and were then culled 4 h after treatment \[[@CR46]\]; animals in our study were treated for 14 days and culled 18 h later. Therefore, we primarily investigated effects caused by subchronic metformin treatment. Second, disparities in our studies could be due to differences between liver and retinal tissue. That metformin may have varied effects in diverse tissues over time is supported by a recent study in which skeletal muscle samples from type 2 diabetic patients, who had taken their last dose of metformin 12 h before biopsy collection, were found to have normal complex I function \[[@CR47]\]. Nonetheless, the effect of metformin within the retina should be examined further.

That metformin treatment did not reverse all diabetic alterations was not unexpected. Previous studies have found that chronic insulin treatment only partially normalised changes in the retinal proteome and transcriptome \[[@CR31], [@CR48]\]. In addition, because HbA~1c~ and glycaemic levels were not fully normalised with metformin in this study, longer and/or more vigorous treatment may produce additional differences in retinal proteins. Although glycaemic regulation substantially decreases the risk of developing diabetic complications, the reduction of ophthalmic complications is closely linked to hypertension control, particularly via the renin--angiotensin system \[[@CR49], [@CR50]\]. A study examining the effect of angiotensin-1 receptor antagonism on the whole retinal proteome of diabetic mice found that 72% of the proteins altered in diabetes were normalised by treatment, and that these were associated with metabolic and apoptotic abnormalities \[[@CR34]\]. The authors did not report whether their animals also received treatment for hyperglycaemia. It would therefore be interesting to examine how the combination of anti-hyperglycaemic and anti-hypertensive treatment affects the diabetic retinal proteome.

In summary, we identified 98 differentially abundant retinal membrane proteins in a mouse model of type 2 diabetes using label-free MS. Network and pathway enrichment analysis indicated defects in proteins involved with electron transport and cell signalling. Metformin treatment partially normalised these changes. Our findings may have relevance to the neuronal dysfunction observed in diabetic retinopathy.
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